RxDoctor Payments Data

Andy Yu, MD

Internal Medicine · San Jose, CANPI 1427136266

Payments from drug & device makers

$45,371in general payments, 2019–2025

Across 381 payments — averaging $119.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$44K
  • Braintree Laboratories, Inc.$410
  • AbbVie$375
  • Takeda Pharmaceuticals U.S.A., Inc.$125
  • Madrigal Pharmaceuticals$125
  • Phathom Pharmaceuticals, Inc.$124
  • plus $398 from 6 others

What the payments were for

  • Speaking & faculty fees$38,19084%
  • Travel & lodging$1,1072%
  • Food & beverage$5,66412%
  • Gifts$4101%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$45,371 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$108,604
Medicare patients
261
Services billed
713

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VemlidyTenofovir Alafenamide162$241,447
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates178$12,128
Mesalamine ErMesalamine18$9,580
Entecavir50$6,070
Lamivudine HbvLamivudine14$5,663
Mesalamine15$4,659
Ursodiol12$2,688
Famotidine178$2,026
Tenofovir Disoproxil Fumarate17$1,531
Omeprazole152$1,006
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg28$541
Hydrocortisone17$495

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadVemlidy$43,814$241,447162 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Jose

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →